These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18690499)

  • 1. Postmarketing evidence of disease-modifying drugs in multiple sclerosis.
    Trojano M; Paolicelli D; Fuiani A; Pellegrini F; Iaffaldano P; Direnzo V; D'Onghia M
    Neurol Sci; 2008 Sep; 29 Suppl 2():S225-6. PubMed ID: 18690499
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?
    Trojano M; Paolicelli D; Tortorella C; Iaffaldano P; Lucchese G; Di Renzo V; D'Onghia M
    Neurol Clin; 2011 May; 29(2):309-21. PubMed ID: 21439443
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-marketing of disease modifying drugs in multiple sclerosis: an exploratory analysis of gender effect in interferon beta treatment.
    Trojano M; Pellegrini F; Paolicelli D; Fuiani A; Zimatore GB; Tortorella C; Simone IL; Patti F; Ghezzi A; Portaccio E; Rossi P; Pozzilli C; Salemi G; Lugaresi A; Bergamaschi R; Millefiorini E; Clerico M; Lus G; Vianello M; Avolio C; Cavalla P; Iaffaldano P; Direnzo V; D'Onghia M; Lepore V; Livrea P; Comi G; Amato MP;
    J Neurol Sci; 2009 Nov; 286(1-2):109-13. PubMed ID: 19615696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Natalizumab: a country-based surveillance program.
    Mancardi GL; Amato MP; D'Alessandro R; Drago F; Milanese C; Popoli P; Provinciali L; Rossi P; Savettieri G; Tedeschi G; Tola MR; Vanacore N; Covezzoli A; De Rosa M; Piccinni C; Montanaro N; Periotto L; Addis A; Martini N
    Neurol Sci; 2008 Sep; 29 Suppl 2():S235-7. PubMed ID: 18690503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disease-modifying agents in the treatment of multiple sclerosis: a review of long-term outcomes.
    Katrych O; Simone TM; Azad S; Mousa SA
    CNS Neurol Disord Drug Targets; 2009 Dec; 8(6):512-9. PubMed ID: 19811446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
    Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
    Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. You get what you measure: evaluating endpoints in MS clinical trials.
    Marrie RA
    Neurology; 2008 Aug; 71(9):620-1. PubMed ID: 18685132
    [No Abstract]   [Full Text] [Related]  

  • 8. Modern multiple sclerosis treatment - what is approved, what is on the horizon.
    Pilz G; Wipfler P; Ladurner G; Kraus J
    Drug Discov Today; 2008 Dec; 13(23-24):1013-25. PubMed ID: 18775508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can we quantify the benefits of DMDs in multiple sclerosis?
    Thompson A
    Lancet Neurol; 2006 Apr; 5(4):290-1. PubMed ID: 16545743
    [No Abstract]   [Full Text] [Related]  

  • 10. Coming of age: the use of immunomodulatory therapy in children with multiple sclerosis.
    Banwell B; Tremlett H
    Neurology; 2005 Mar; 64(5):778-9. PubMed ID: 15753408
    [No Abstract]   [Full Text] [Related]  

  • 11. Confounders in natural history of interferon-beta-treated relapsing multiple sclerosis.
    Gout O
    Ann Neurol; 2008 Jan; 63(1):126; author reply 126-7. PubMed ID: 17702028
    [No Abstract]   [Full Text] [Related]  

  • 12. Interferon-beta responders and non-responders. A biological approach.
    Bertolotto A; Gilli F
    Neurol Sci; 2008 Sep; 29 Suppl 2():S216-7. PubMed ID: 18690496
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of natalizumab in Belgian multiple sclerosis patients: subgroup analysis of the natalizumab observational program.
    van Pesch V; Bartholomé E; Bissay V; Bouquiaux O; Bureau M; Caekebeke J; Debruyne J; Declercq I; Decoo D; Denayer P; De Smet E; D'hooghe M; Dubois B; Dupuis M; Sankari SE; Geens K; Guillaume D; van Landegem W; Lysandropoulos A; de Noordhout AM; Medaer R; Melin A; Peeters K; Ba RP; Retif C; Seeldrayers P; Symons A; Urbain E; Vanderdonckt P; Van Ingelghem E; Vanopdenbosch L; Vanroose E; Van Wijmeersch B; Willekens B; Willems C; Sindic C
    Acta Neurol Belg; 2014 Sep; 114(3):167-78. PubMed ID: 24915752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medication use in a large international sample of people with multiple sclerosis: associations with quality of life, relapse rate and disability.
    Jelinek GA; Weiland TJ; Hadgkiss EJ; Marck CH; Pereira N; van der Meer DM
    Neurol Res; 2015 Aug; 37(8):662-73. PubMed ID: 25905471
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How effective are disease-modifying drugs in delaying progression in relapsing-onset MS?
    Brown MG; Kirby S; Skedgel C; Fisk JD; Murray TJ; Bhan V; Sketris IS
    Neurology; 2007 Oct; 69(15):1498-507. PubMed ID: 17699802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cyclophosphamide-based combination therapies for autoimmunity.
    Perini P; Calabrese M; Rinaldi L; Gallo P
    Neurol Sci; 2008 Sep; 29 Suppl 2():S233-4. PubMed ID: 18690502
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon beta in multiple sclerosis: how much BENEFIT?
    Pittock SJ
    Lancet; 2007 Aug; 370(9585):363-4. PubMed ID: 17678997
    [No Abstract]   [Full Text] [Related]  

  • 18. Teriflunomide for multiple sclerosis.
    He D; Zhang C; Zhao X; Zhang Y; Dai Q; Li Y; Chu L
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009882. PubMed ID: 27003123
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Teriflunomide for multiple sclerosis.
    He D; Xu Z; Dong S; Zhang H; Zhou H; Wang L; Zhang S
    Cochrane Database Syst Rev; 2012 Dec; 12():CD009882. PubMed ID: 23235682
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trials of multiple sclerosis therapies: improvements to demonstrate long-term patient benefit.
    Carroll WM
    Mult Scler; 2009 Aug; 15(8):951-8. PubMed ID: 19465446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.